Pathologic response to neoadjuvant chemotherapy in stage II and III breast cancer can be predicted accurately by FDG PET after two courses of chemotherapy.

No abstract

This study aimed to evaluate the long-term prognostic usefulness of 18 F-FDG PET for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEPNETs). Methods: Thirty-eight patients with metastatic GEPNETs were prospectively enrolled. Initial check-up comprised CT scan, 111 In-pentetreotide scintigraphy (SRS), and 18 F-FDG PET. Only 18 F-FDG PET-positive lesions with a maximum standardized uptake value (SUV max ) greater than 4.5 or an SUV ratio (SUV max tumor to SUV max nontumoral liver tissue, or T/NT ratio) of 2.5 or greater were considered positive for prognosis-that is, indicating a poor prognosis. Progressionfree survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Factors associated with survival were assessed with univariate and multivariate analyses, using the Cox regression model. Results: Median PFS and OS were significantly higher for patients with a negative 18 F-FDG PET finding, with an OS of 119.5 mo (95% confidence interval [CI], 72-∞), than for patients with a positive 18 F-FDG PET finding (only 15 mo [95% CI, 4-27]) (P , 10 −3 ). Median PFS and OS were significantly higher for the patient group that had a positive SRS than the group with a negative SRS (P 5 0.0002). For patients with a positive SRS, PFS and OS were significantly shorter when the 18 F-FDG PET finding was positive: 19.5 mo (95% CI, 4-37) for PFS and 119.5 mo (95% CI, 81-∞) for OS (P , 10 −3 ). In the patient group with a lowgrade GEPNET and a positive SRS, PFS and OS were also significantly lower for patients with a positive 18 F-FDG PET. At 48-mo follow-up, 100% of patients who had a positive 18 F-FDG PET for disease progression (of which 47% were also SRS-positive) were deceased, and 87% of patients with a negative 18 F-FDG PET were alive (P , 0.0001). The T/NT ratio was the only parameter associated with OS on multivariate analysis. Conclusion: Overall, 18 F-FDG PET appears to be of major importance in the prognostic evaluation of metastatic GEPNET. A positive 18 F-FDG PET with an SUV ratio (T/NT) of 2.5 or greater was a poor prognostic factor, with a 4-y survival rate of 0%. A positive SRS does not eliminate the need for performing 18 F-FDG PET, which is of greater prognostic utility.

No abstract